John Whitehead

List of Publications by Citations

87 papers	3,269 citations	27 h-index	55 g-index
93 ext. papers	3,629 ext. citations	3.6 avg, IF	5.19 L-index

#	Paper	IF	Citations
87	A general parametric approach to the meta-analysis of randomized clinical trials. *Statistics in Medicine*, **1991**, 10, 1665-77	2.3	591
86	Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. *Lancet, The*, **2000**, 355, 1949-54	40	260
85	Sample size calculations for ordered categorical data. *Statistics in Medicine*, **1993**, 12, 2257-71	2.3	217
84	On the bias of maximum likelihood estimation following a sequential test. *Biometrika*, **1986**, 73, 573-581	2	195
83	Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. *SpringerPlus*, **2015**, 4, 709		129
82	Bayesian decision procedures for dose determining experiments. *Statistics in Medicine*, **1995**, 14, 885-93; discussion 895-9	2.3	120
81	Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. *PLoS Medicine*, **2016**, 13, e1001997	11.6	116
80	Bayesian decision procedures based on logistic regression models for dose-finding studies. *Journal of Biopharmaceutical Statistics*, **1998**, 8, 445-67	1.3	87
79	A random effects model for ordinal responses from a crossover trial. *Statistics in Medicine*, **1991**, 10, 901-6; discussion 906-7	2.3	68
78	Sequential forms of the log rank and modified Wilcoxon tests for censored data. *Biometrika*, **1979**, 66, 105-113	2	68
77	Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. *Biostatistics*, **2001**, 2, 47-61	3.7	63
76	Bayesian methods for the design and interpretation of clinical trials in very rare diseases. *Statistics in Medicine*, **2014**, 33, 4186-201	2.3	60
75	Overrunning and underrunning in sequential clinical trials. *Contemporary Clinical Trials*, **1992**, 13, 106-21		60
74	Experimental Treatment of Ebola Virus Disease with Brincidofovir. *PLoS ONE*, **2016**, 11, e0162199	3.7	59
73	Decision theoretic designs for phase II clinical trials with multiple outcomes. *Biometrics*, **1999**, 55, 971-7	1.8	52
72	Sample sizes for phase II and phase III clinical trials: an integrated approach. *Statistics in Medicine*, **1986**, 5, 459-64	2.3	50
71	Mid-trial design reviews for sequential clinical trials. *Statistics in Medicine*, **2001**, 20, 165-76	2.3	43

70	A unified theory for sequential clinical trials. *Statistics in Medicine*, **1999**, 18, 2271-86	2.3	43
69	Evaluating clinical trial designs for investigational treatments of Ebola virus disease. *PLoS Medicine*, **2015**, 12, e1001815	11.6	39
68	Bayesian sample size for exploratory clinical trials incorporating historical data. *Statistics in Medicine*, **2008**, 27, 2307-27	2.3	36
67	Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. *Statistics in Medicine*, **2006**, 25, 37-53	2.3	34
66	Bayesian decision procedures for binary and continuous bivariate dose-escalation studies. *Pharmaceutical Statistics*, **2006**, 5, 125-33	1	33
65	Decision-making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts. *Pharmaceutical Statistics*, **2005**, 4, 119-128	1	31
64	A novel Bayesian decision procedure for early-phase dose-finding studies. *Journal of Biopharmaceutical Statistics*, **1999**, 9, 583-97	1.3	30
63	Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa. *PLoS ONE*, **2015**, 10, e0120981	3.7	29
62	Interim analyses and sequential designs in phase III studies. *British Journal of Clinical Pharmacology*, **2001**, 51, 394-9	3.8	28
61	One- and two-stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint. *Statistics in Medicine*, **2009**, 28, 828-47	2.3	27
60	Stopping rules for phase II studies. *British Journal of Clinical Pharmacology*, **2001**, 51, 523-9	3.8	27
59	Formal approaches to safety monitoring of clinical trials in life-threatening conditions. *Statistics in Medicine*, **2000**, 19, 2899-917	2.3	27
58	Designing Phase II Studies in the Context of a Programme of Clinical Research. *Biometrics*, **1985**, 41, 373	1.8	26
57	Stopping clinical trials by design. *Nature Reviews Drug Discovery*, **2004**, 3, 973-7	64.1	25
56	An evaluation of Bayesian designs for dose-escalation studies in healthy volunteers. *Statistics in Medicine*, **2006**, 25, 433-45	2.3	24
55	A Bayesian dose-finding procedure for phase I clinical trials based only on the assumption of monotonicity. *Statistics in Medicine*, **2010**, 29, 1808-24	2.3	23
54	The analysis of relapse clinical trials, with application to a comparison of two ulcer treatments. *Statistics in Medicine*, **1989**, 8, 1439-54	2.3	22
53	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. *Statistics in Biopharmaceutical Research*, **2020**, 12, 483-497	1.2	22

52	Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment. *Statistics in Medicine*, **2003**, 22, 677-87	2.3	21
51	Analysis of failure time data with ordinal categories of response. *Statistics in Medicine*, **1991**, 10, 1703-10	2.3	20
50	The case for frequentism in clinical trials. *Statistics in Medicine*, **1993**, 12, 1405-13; discussion 1415-9	2.3	19
49	The double triangular test: a sequential test for the two-sided alternative with early stopping under the null hypothesis. *Sequential Analysis*, **1990**, 9, 117-136	0.7	19
48	Learning from previous responses in phase I dose-escalation studies. *British Journal of Clinical Pharmacology*, **2001**, 52, 1-7	3.8	18
47	On being the statistician on a Data and Safety Monitoring Board. *Statistics in Medicine*, **1999**, 18, 3425-34	2.3	18
46	Sequential designs for equivalence studies. *Statistics in Medicine*, **1996**, 15, 2703-15	2.3	17
45	An exact method for analysis following a two-stage phase II cancer clinical trial. *Statistics in Medicine*, **2010**, 29, 3118-25	2.3	16
44	Trial design for evaluating novel treatments during an outbreak of an infectious disease. *Clinical Trials*, **2016**, 13, 31-8	2.2	15
43	Group sequential trials revisited: simple implementation using SAS. *Statistical Methods in Medical Research*, **2011**, 20, 635-56	2.3	15
42	Designing exploratory cancer trials using change in tumour size as primary endpoint. *Statistics in Medicine*, **2013**, 32, 2544-54	2.3	14
41	A Bayesian approach for dose-escalation in a Phase I clinical trial incorporating pharmacodynamic endpoints. *Journal of Biopharmaceutical Statistics*, **2007**, 17, 1117-29	1.3	14
40	A simple two-stage design for quantitative responses with application to a study in diabetic neuropathic pain. *Pharmaceutical Statistics*, **2009**, 8, 125-35	1	13
39	Sequential genome-wide association studies for monitoring adverse events in the clinical evaluation of new drugs. *Statistics in Medicine*, **2006**, 25, 3081-92	2.3	13
38	The double triangular test in practice. *Pharmaceutical Statistics*, **2004**, 3, 39-49	1	13
37	An improved approximation for calculation of confidence intervals after a sequential clinical trial. *Statistics in Medicine*, **1990**, 9, 1277-85	2.3	13
36	Devising two-stage and multistage phase II studies on systemic adjuvant therapy for uveal melanoma **2012**, 53, 4986-9		12
35	A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer. *Statistics in Medicine*, **2012**, 31, 1931-43	2.3	12

34	Bayesian adaptive dose-escalation procedures for binary and continuous responses utilizing a gain function. *Pharmaceutical Statistics*, **2015**, 14, 479-87	1	11
33	Bayesian procedures for phase I/II clinical trials investigating the safety and efficacy of drug combinations. *Statistics in Medicine*, **2011**, 30, 1952-70	2.3	11
32	A parametric multistate model for the analysis of carcinogenicity experiments. *Lifetime Data Analysis*, **1995**, 1, 327-46	1.3	11
31	Using historical lesion volume data in the design of a new phase II clinical trial in acute stroke. *Stroke*, **2009**, 40, 1347-52	6.7	10
30	Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. *Pharmaceutical Statistics*, **2009**, 8, 136-49	1	10
29	A random effects model for ordinal responses from a crossover trial. *Statistics in Medicine*, **1993**, 12, 2147-51	2.3	10
28	One-stage and two-stage designs for phase II clinical trials with survival endpoints. *Statistics in Medicine*, **2014**, 33, 3830-43	2.3	9
27	A combined score test for binary and ordinal endpoints from clinical trials. *Statistics in Medicine*, **2010**, 29, 521-32	2.3	9
26	Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. *BMJ Open*, **2015**, 5, e009566	3	8
25	Using Bayesian Decision Theory in Dose-Escalation Studies **2006**, 149-171		8
24	Incorporating data received after a sequential trial has stopped into the final analysis: implementation and comparison of methods. *Biometrics*, **2003**, 59, 701-9	1.8	8
23	Predicting the Duration of Sequential Survival Studies. *Drug Information Journal*, **2001**, 35, 1387-1400		7
22	TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. *Clinical Infectious Diseases*, **2020**, 70, 2062-2072	11.6	7
21	Bayesian sample sizes for exploratory clinical trials comparing multiple experimental treatments with a control. *Statistics in Medicine*, **2015**, 34, 2048-61	2.3	6
20	A sequential trial of pain killers in arthritis: issues of multiple comparisons with control and of interval-censored survival data. *Journal of Biopharmaceutical Statistics*, **1997**, 7, 333-53	1.3	6
19	Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints. *Statistics in Medicine*, **2015**, 34, 1889-903	2.3	5
18	How a sequential design would have affected the GAIN International Study of gavestinel in stroke. *Cerebrovascular Diseases*, **2004**, 17, 111-7	3.2	5
17	Statistical Methods for Ordered Categorical Data Based on a Constrained Odds Model. *Biometrical Journal*, **2003**, 45, 453-470	1.5	5

16	On the Unreliability of Multiple Systems Estimation for Estimating the Number of Potential Victims of Modern Slavery in the UK. *Journal of Human Trafficking*, **2021**, 7, 1-13	0.9	5
15	Estimation of treatment effects following a sequential trial of multiple treatments. *Statistics in Medicine*, **2020**, 39, 1593-1609	2.3	4
14	An evaluation of methods for testing hypotheses relating to two endpoints in a single clinical trial. *Pharmaceutical Statistics*, **2012**, 11, 107-17	1	3
13	Comparison of the information in two lung function experiments. *Statistics in Medicine*, **1989**, 8, 861-70	2.3	3
12	Prospective epidemiological studies involving paired organs. *Statistics in Medicine*, **1988**, 7, 619-25	2.3	2
11	GOST: A generic ordinal sequential trial design for a treatment trial in an emerging pandemic. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005439	4.8	2
10	Partial stochastic dominance for the multivariate Gaussian distribution. *Statistics and Probability Letters*, **2015**, 103, 80-85	0.6	1
9	A bivariate Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis. *Pharmaceutical Statistics*, **2012**, 11, 476-84	1	1
8	Determining an Adaptive Exclusion Procedure following Discovery of an Association between the Whole Genome and Adverse Drug Reactions. *Drug Information Journal*, **2010**, 44, 147-157		1
7	Bayesian ADEPT Developers' Response. *Pharmaceutical Statistics*, **2003**, 2, 221-221	1	1
6	Preferential prescribing of oral corticosteroids in Irish male asthmatic children. *British Journal of Clinical Pharmacology*, **2001**, 52, 319-21	3.8	1
5	Whitehead et al. Response to Misunderstandings of Multiple Systems Estimation. *Journal of Human Trafficking*, **2020**, 1-5	0.9	0
4	A comparison of the barely Bayesian design with the triangular test for clinical trials in infectious diseases. *Clinical Trials*, **2016**, 13, 451-3	2.2	
3	Estimation strategies for reacting to the identification of an association between the genome and adverse drug reactions. *Journal of Biopharmaceutical Statistics*, **2011**, 21, 111-24	1.3	
2	A safety monitoring procedure for a clinical drug development program, with application to the assessment of a novel COX-2 inhibitor. *Journal of Biopharmaceutical Statistics*, **2008**, 18, 737-49	1.3	
1	Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug-development programme. *Pharmaceutical Statistics*, **2009**, 8, 287-300	1	